CRUK

The American Association for Cancer Research annual meeting wrapped up today in Chicago. Below are selected business briefs from the conference.

The company is collaborating with two UK institutes to assess whether its Signatera ctDNA technology can detect disease recurrence in women treated for breast cancer.

Areas of concern are the recruitment of talented scientists, as well as retaining access to EU funding, European research collaborations, and clinical trials.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

The two studies came out of the UK's Tracking Cancer Evolution through Therapy (TRACERx) trial.

Speakers at the conference's opening plenary showed how their work in cancer research fit into the broad theme of 'Discover, Predict, Prevent, Treat.'

The new funding supports clinical trials as well as preclinical work to identify biomarkers of therapeutic response. 

The researchers will sequence the genomes and transcriptomes of 250 breast cancer patients in the first phase, returning information from 16 actionable genes. 

Inivata plans to use the new funds to accelerate clinical studies to validate its liquid biopsy technology platform and commercialize its first products.

The work identified specific groups of somatic mutations that might be ideal to hunt for in ctDNA to monitor tumor burden, guide treatment, or follow therapeutic response.

Pages

Mice in New York harbor both antibiotic-resistant bacteria and novel viruses, according to a new analysis of their fecal microbiomes.

Human Heredity and Health in Africa Initiative has issued guidelines for genomic research in the region, according to Nature News.

The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.

In Genome Biology this week: approach to analyze alternative polyadenylation, algorithm to predict transcriptomic structural variations, and more.